Table 3.
Survival analysis between immunohistochemical expression of p53, p21, nm23 and VEGF with 2-year, 5-year and overall survival.
| Variable | Number (n=419) |
2-year OS p-value a |
2-yearOS HR(95% CI) a |
5-year p-value a |
5-yearOS HR(95% CI) a |
Overall survival p-value a |
Overall survival HR(95% CI) a |
|---|---|---|---|---|---|---|---|
| P53 | |||||||
| - | 164 | 1.000 | 1.000 | ||||
| + | 255 | 0.731 | 1.070(0.729-1.569) | 0.410 | 1.142(0.832-1.568) | 0.284 | 1.178(0.873-1.591) |
| p21 | |||||||
| - | 307 | 1.000 | 1.000 | ||||
| + | 112 | 0.722 | 1.077(0.715-1.623) | 0.803 | 0.958(0.686-1.340) | 0.997 | 0.999(0.732-1.365) |
| nm23 | |||||||
| - | 43 | 1.000 | 1.000 | ||||
| + | 376 | 0.779 | 0.913(0.484-1.722) | 0.650 | 0.895(0.554-1.445) | 0.971 | 0.992(0.631-1.558) |
| VEGF | |||||||
| - | 99 | 1.000 | 1.000 | ||||
| + | 320 | 0.040 | 1.652(1.024-2.665) | 0.152 | 1.310(0.905-1.896) | 0.130 | 1.303(0.925-1.834) |
Notes: aAdjusted for drinking status, BCLC stages, PVTT, radical hepatic resection and adjuvant antiviral treatment. OS, overall survival; HR, hazard ratio; CI, confidence interval.